[CAS NO. 320725-47-1] Squalaminelactate
PRODUCTS SPECIFICATIONS [320725-47-1]
DESCRIPTION [320725-47-1]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 718.04 |
| Molecular Formula | C37H71N3O8S |
| SMILES | NCCCCNCCCN[C@H]1CC[C@@]2(C)[C@](C[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CC[C@@H](OS(=O)(O)=O)C(C)C)([H])C1.C[C@@H](C(O)=O)O |
Summary
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.
In Vitro
Squalamine lactate has a more generalized effect on the cellular signaling cascade that is common to both VEGF and other growth factors [1] . Squalamine blocks the action of VEGF and integrin expression, thereby inhibiting angiogenesis, when bound to calmodulin [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Squalamine is ineffective when administered intravitreally and therefore requires intravenous dosing. However, systemic dosing has yielded promising results in rats as well as humans [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02349516 | Starr Muscle|Ohr Pharmaceutical Inc.|Prism Vision Group |
Diabetic Retinopathy
|
February 2015 | Phase 2 |
| NCT02511613 | Ohr Pharmaceutical Inc. |
Age-Related Macular Degeneration
|
July 2015 | Phase 2 |
| NCT00021385 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) |
Ovarian Cancer
|
May 2001 | Phase 2 |
| NCT01769183 | Elman Retina Group |
Retinal Neovascularization
|
February 2013 | Phase 2 |
| NCT02614937 | Ohr Pharmaceutical Inc.|Cumberland Valley Retina Consultants, PC |
Retinal Vein Occlusion|Macular Edema
|
April 2013 | Phase 1|Phase 2 |
| NCT00089830 | Genaera Corporation |
Macular Degeneration
|
August 2004 | Phase 2 |
| NCT00244920 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) |
Prostate Cancer
|
January 2002 | Phase 2 |
| NCT02727881 | Ohr Pharmaceutical Inc. |
Age-related Macular Degeneration
|
April 12, 2016 | Phase 3 |
| NCT01678963 | Ohr Pharmaceutical Inc. |
Neovascular Age Related Macular Degeneration
|
November 2012 | Phase 2 |
| NCT00139282 | Genaera Corporation |
Wet Age-Related Macular Degeneration
|
June 2005 | Phase 3 |
| NCT00333476 | Genaera Corporation |
Macular Degeneration
|
May 2006 | Phase 2 |
| NCT00094120 | Genaera Corporation |
Macular Degeneration
|
October 2004 | Phase 2 |
Appearance
Solid
Source
Squalus acanthias
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : ≥ 36.66 mg/mL ( 51.06 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.3927 mL | 6.9634 mL | 13.9268 mL |
| 5 mM | 0.2785 mL | 1.3927 mL | 2.7854 mL |
| 10 mM | 0.1393 mL | 0.6963 mL | 1.3927 mL |
References
- [1] Hussain RM, et al. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opin Emerg Drugs. 2017 Sep;22(3):235-246.
- [2] Emerson MV, et al. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008 Jun;2(2):377-88.